Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 20/20 | 0.56 |
| ▸ | S1PR5 | Q9H228 | 9/20 | 0.56 |
| ▸ | S1PR3 | Q99500 | 9/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12601139 | 0.94 | S1PR1 (0.54) | S1PR1S1PR5S1PR3CYP3A4CYP2C9 | |
| SCHEMBL2030568 | 0.93 | S1PR1 (0.52) | S1PR1S1PR5S1PR3CYP3A4CYP2C9 | |
| SCHEMBL1981953 | 0.93 | S1PR1 (0.52) | S1PR1S1PR5S1PR3CYP3A4CYP2C9 | |
| SCHEMBL12600665 | 0.92 | S1PR1 (0.65) | S1PR1S1PR5S1PR3 | |
| SCHEMBL1398432 | 0.91 | S1PR1 (0.59) | S1PR1S1PR5S1PR3KCNH2 | |
| SCHEMBL1980495 | 0.89 | S1PR1 (0.61) | S1PR1S1PR5S1PR3CYP2C9 | |
| SCHEMBL3311581 | 0.88 | S1PR1 (0.61) | S1PR1S1PR5S1PR3CYP2C9 | |
| SCHEMBL13644166 | 0.87 | S1PR1 (0.53) | S1PR1S1PR5S1PR3CYP3A4CYP2C9 | |
| SCHEMBL1398553 | 0.86 | S1PR1 (0.62) | S1PR1S1PR5S1PR3KCNH2 | |
| SCHEMBL2006447 | 0.86 | S1PR1 (0.56) | S1PR1S1PR5S1PR3CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120283297-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | GLAXO WELLCOME HOUSE (GB) | 2012-11-08 | — | — | US | disclosed |
| EP-2513095-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | Glaxo Group Limited (GB) | 2012-10-24 | — | — | EP | disclosed |
| WO-2011072488-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011072488-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283297-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885S1PR5 4/4885S1PR3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.